Nxera Pharma reports strong Q1 2026 growth with key licensing deals and milestone payments boosting profits.

Nxera Pharma announced robust operational and financial results for Q1 2026, driven by new licensing agreements, including a deal with Santhera for Duchenne Muscular Dystrophy treatment in Asia-Pacific. The company achieved multiple R&D milestones, resulting in significant milestone payments and improved profitability, with net profit rising to JPY 1.79 billion from a prior loss. Strategic partnerships, including the acquisition of Centessa Pharmaceuticals by Eli Lilly, position Nxera for continued growth. Nxera expects 2026 to be a pivotal year for sustained growth and value creation for patients and shareholders.